Align Technology is the leading manufacturer of clear aligners... Show more
ALGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where ALGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on August 19, 2025. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on August 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGN as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ALGN entered a downward trend on September 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.390) is normal, around the industry mean (10.825). P/E Ratio (21.791) is within average values for comparable stocks, (56.185). ALGN's Projected Growth (PEG Ratio) (0.765) is slightly lower than the industry average of (1.750). ALGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (2.404) is also within normal values, averaging (14.891).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
a manufacturer of the invisalign system for treating malocclusion
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
RPV | 98.65 | 0.94 | +0.96% |
Invesco S&P 500® Pure Value ETF | |||
ELC | 21.68 | -0.10 | -0.44% |
Entergy Louisiana LLC | |||
SXQG | 33.37 | -0.25 | -0.74% |
ETC 6 Meridian Quality Growth ETF | |||
EKG | 17.41 | -0.19 | -1.08% |
First Trust Nasdaq Lux Dgtl Hlth SoluETF | |||
TBT | 34.05 | -0.44 | -1.28% |
ProShares UltraShort 20+ Year Treasury |
A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with BAX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then BAX could also see price increases.
Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
---|---|---|---|---|
ALGN | 100% | -1.66% | ||
BAX - ALGN | 62% Loosely correlated | +0.22% | ||
JNDOF - ALGN | 60% Loosely correlated | N/A | ||
LUNG - ALGN | 54% Loosely correlated | -1.09% | ||
ITGR - ALGN | 44% Loosely correlated | -0.48% | ||
NVST - ALGN | 43% Loosely correlated | -0.24% | ||
More |
Ticker / NAME | Correlation To ALGN | 1D Price Change % |
---|---|---|
ALGN | 100% | -1.66% |
Pharmaceuticals category (388 stocks) | 27% Poorly correlated | -0.30% |
Pharmaceuticals: Other category (103 stocks) | 26% Poorly correlated | -0.53% |